|本期目录/Table of Contents|

[1]王国平,李霞,何朗,等.奥氮平联合盐酸吗啡缓释片治疗癌性疼痛的疗效和安全性分析[J].医学研究与战创伤救治(原医学研究生学报),2020,22(6):622-626.[doi:10.3969/j.issn.1672-271X.2020.06.014]
　WANG Guo-ping,LI Xia,HE Lang,et al.Effect and safety analysis of olanzapine combined with morphine hydrochloride sustained release tablets in the treatment of cancerous pain[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2020,22(6):622-626.[doi:10.3969/j.issn.1672-271X.2020.06.014]
点击复制

奥氮平联合盐酸吗啡缓释片治疗癌性疼痛的疗效和安全性分析()
分享到62.8K

《医学研究与战创伤救治》（原医学研究生学报）[ISSN:1672-271X/CN:32-1713/R]

卷:
第22卷
期数:
2020年6期
页码:
622-626
栏目:
临床研究
出版日期:
2020-11-20

文章信息/Info

Title:
Effect and safety analysis of olanzapine combined with morphine hydrochloride sustained release tablets in the treatment of cancerous pain
作者:
王国平; 李霞; 何朗; 张燕
作者单位：611130成都，成都中医药大学附属第五人民医院肿瘤科（王国平、李霞、何朗）；646000泸州，泸州市人民医院肿瘤科（张燕）
Author(s):
WANG Guo-ping1;  LI Xia1;  HE Lang1;  ZHANG Yan2
(1.Department of Oncology，the Fifth People′s Hospital Affiliated to Chengdu University of Traditional Chinese Medicine，Chengdu 611130，Sichuan，China; 2.Department of Oncology，Luzhou People′s Hospital, Luzhou 646000，Sichuan，China)
关键词:
奥氮平; 盐酸吗啡缓释片; 癌; 疼痛
Keywords:
olanzapine;  morphine hydrochloride sustained release tablets;  cancer;  pain
分类号:
Ｒ730.53
DOI:
10.3969/j.issn.1672-271X.2020.06.014
文献标志码:
A
摘要:
目的观察奥氮平联合盐酸吗啡缓释片治疗晚期癌症伴中、重度癌痛的疗效和不良反应。方法回顾性分析2015年１月至2019年6月成都市第五人民医院肿瘤科收治的伴中、重度癌痛的125例晚期癌症患者资料，按癌痛不同止痛治疗方法分为2组：采用奥氮平联合盐酸吗啡缓释片治疗的62例为联合组，单独使用盐酸吗啡缓释片治疗的63例为对照组。2组均在常规治疗基础上起始使用盐酸吗啡缓释片10～30 ｍg止痛治疗，每12小时给药1次，治疗时间2周，联合组在使用盐酸吗啡缓释片基础上每天睡前服用奥氮平5～10 mg，根据疼痛缓解程度调整盐酸吗啡缓释片的剂量，最大剂量270 ｍg/次，分析比较2组患者疼痛缓解情况及焦虑、抑郁和生活质量的改善情况，以及不良反应。结果治疗后1周及2周，联合组患者疼痛评分分别为(6.1±0.3)分和(2.8±0.7)分，明显低于对照组(7.5±0.6)分和(5.4±0.1)分（P<0.05）；联合组患者焦虑、抑郁评分分别为(7.67±3.14)分和(7.04±3.26)分，明显低于对照组(8.06±3.35)分和(7.96±4.13)分（P<0.05），且随着用药治疗时间的延长，改善更加明显（P<0.05）。联合组患者生活质量领域各项评分改善均明显优于对照组（P<0.05）。2组不良反应相近，可控性强，安全性好，除恶心呕吐外差异无统计学意义（P>0.05）。结论奥氮平联合盐酸吗啡缓释片治疗中、重度癌痛止痛效果较好，且能改善患者焦虑、抑郁状态及生活质量，不良反应小，安全性好，值得临床推广使用。
Abstract:
ObjectiveTo observe the curative effect and adverse reaction of olanzapine combined with morphine hydrochloride sustained release tablets in the treatment of advanced malignant tumors with moderate and severe cancerous pain.MethodsFrom January 2015 to June 2019，125 cases of advanced cancer with moderate or severe cancer pain were analyzed retrospectively. Among them，62 cases were treated with olanzapine combined with morphine hydrochloride sustained-release tablets (combined group)，63 cases were treated with morphine hydrochloride sustained-release tablets alone (control group). All patients were initially treated with morphine hydrochloride mild release tablets 10-30mg for pain relief on the basis of regular treatment of malignant tumors，onceevery 12h. The treatment time was 2 weeks. The patients in the combined group took 5-10 mg of olanzapine daily before going to bed on the basis ofmorphine hydrochloride sustained release tablets. The dose of morphine hydrochloride sustained release tablets was adjusted according to the degree of pain relief. The maximum dose was 270mg each time. The pain relief，anxiety，depression and improvement of quality of life was observed.ResultsAfter 1 week and 2 weeks treatment，the pain scores of patients in the combined group were （6.1±0.3） and （2.8±0.7），significantly lower than those in the control group （7.5±0.6） and （5.4±0.1），（P<0.05). The scores of anxiety and depression in the combined group were （7.67±3.14） and （7.04 ±3.26）, respectively, which was significantly lower than that in the control group （8.06 ±3.35） and （7.96 ±4.13）,（P<0.05). The improvement was more obvious with the extension of treatment time (P<0.05). The scores of quality of life in the combined group were significantly better than those in the control group (P<0.05). The adverse reactions of two groups were similar，controllable and safe (P>0.05).ConclusionOrazapine combined with morphine hydrochloride sustained release tablets are effective in the treatment of moderate and severe cancerous pain and pain relief，and also can improve the patient′s anxiety and depression status and quality of life. The adverse reaction is small and the safety is better，and it is worth clinical promotion.

参考文献/References:

[1]卜岗,孙欣,王辉,等.盐酸羟考酮缓释片联合氟哌噻吨美利曲辛片治疗晚期癌痛的疗效观察[J].现代肿瘤医学,2018,26(4):609-612.
[2]Lie HC,Hiermstad MJ,Fayers P,et al.Depression in advanced Cancer-assessment challenges and associations with disease load[J].J Affect Disord,2015,173(3):176-184.
[3]谢琦,钟慧,黄俊杰.癌痛规范化治疗在肺癌疼痛患者中的应用效果观察[J].基层医学论坛,2019,23(23):3386-3387.
[4]Sexton J,Atayee RS,Bruner HC.Case Report:Ketamine for Pain and Depression in Advanced Cancer[J].J Palliat Med,2018,21(11): 1670-1673.
[5]Bouhassia D，Luporsi E，Krakowski I.Prevalence and incidence of chronic pain with or without neuropathic characteristics in patients with cancer[J].Pain，2017，158(6):1118-1125.
[6]苏琴,王晔琳,李丽.心理干预护理联合癌痛规范化治疗对晚期癌症患者生活质量的效果评价[J].实用临床护理学电子杂志,2018,3(19):152-154.
[7]彭雷，戚焕鹏，翟西菊. 奥氮平辅助治疗肺癌骨转移重度疼痛及相关性焦虑、抑郁的临床观察［J］. 肿瘤基础与临床，2017，30(1): 46-48.
[8]Hamdy MM，Elbadr MM，Barakat A. Bupropion attenuates morphinetolerance and dependence: possible role of glutamate,norepinephrine,inflammation,and oxidative stress[J].Pharmacol Rep,2018,70:955-962.
[9]Chaefer CP，Tome ME，Davis TP. The opioid epidemic:a central rolefor the blood brain barrier in opioid analgesia and abuse[J]. Fluids Barriers CNS,2017,14:32.
[10]Zigmond AS，Snaith RP.The hospital anxiety and depression Scale［J］.Acta Psychiatr Scand,1983,67（6）：361-370.
[11]饶欣,王长连,许雄伟,等.两种阿片类药物治疗癌痛的决策树分析[J].中国疼痛医学杂志,2016,22(6):448-453.
[12]王术江，李伟彦.阿片类药物在癌痛治疗的剂量滴定与转换[J].东南国防医药，2016，18(9):522-526.
[13]沈陆斐,陈文宇，吕晓东,等.阿片类药物对肺癌疼痛患者心理状态影响的研究[J].中国现代医生,2016,54(5):9-12.
[14]张培新,赵彦南,王春雨.60例癌症患者的心理状况调查［J］.临床肿瘤学杂志,2008,13(10):917-919.
[15]杨灵，宋伟平，陈锃丽,等.乳腺癌患者不同阶段的社会支持与生活质量的相关性研究[J].中华肿瘤杂志,2017,39(3):202-206.
[16]Cheng KK，Lee DT．Effects of pain,fatigue,insomnia,and mood disturbance on functional status and quality of life of elderly patients with cancer[J].Crit Rev Oncol Hematol,2011,78 (2):127-137.
[17]Lvgren M,Tishelman C，Sprangers M，et al.Symptoms and problems with functioning among women and men with inoperable lung cancer:A longitudinal study[J].Lung Cancer,2008,60(1):113-124.
[18]刘红军，高献忠，金毅,等.β-血小板衍生生长因子信号通路在吗啡耐受机制中的作用[J]医学研究生学报，2015,28(2):149-152.
[19]李斌,宫羽,张宏江,等.奥氮平联合盐酸羟考酮对晚期肝癌疼痛患者的作用探讨[J]肿瘤药学,2019,9(3):446-450.
[20]汪勇，赵武伟，汪朝晖，等.小剂量奥氮平与奋乃静治疗肝移植术后精神障碍的对照研究[J].东南国防医药，2016,18(11): 572-574.
[21]朱羞阳，佟洋，李驰荣，等．选择性5-羟色胺再摄取抑制剂与奥氮平联合治疗难治性抑郁症的临床疗效［J］.东南国防医药，2013，15(2):125-127.
[22]彭雷,戚焕鹏,翟西菊，等.奥氮平辅助治疗肺癌骨转移重度疼痛及相关性焦虑、抑郁的临床观察[J]肿瘤基础与临床,2017,30（1）：46-48.
[23]杨雪飞,叶知锋,黄挺，等.乌灵胶囊联合奥氮平治疗晚期肿瘤患者相关性焦虑、抑郁状态临床观察[J].新中医，2017,49(4):124-127.
[24]Liu J，Tan L，Zhang H,et al. QoL evaluation of olanzapine for chemotherapy-induced nausea and vomiting comparing with 5-HT3 receptor antagonist[J]. Eur J Cancer Care (Engl),2015,24（3）:436-443.
[25]Flank J，Thackray J，Nielson D,et al.Olanzapine for treatment and prevention of acute chemotherapy-induced vomiting in children: a retrospective，multi-center review[J]. Pediatr Blood Cancer，2015，62(3):496-501.

相似文献/References:

[1]朱羞阳,佟洋,李驰荣,等.选择性5-羟色胺再摄取抑制剂与奥氮平联合治疗难治性抑郁症的临床疗效[J].医学研究与战创伤救治(原医学研究生学报),2013,15(02):125.
　Air force Hangzhou Aviation Medicine Assessment and Training Center,Hangzhou,Zhejiang 00,et al.ZHU Xiu-yang,TONG Yang,LI Chi-rong[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2013,15(6):125.
[2]林小燕,邱 静,王 锐,等.奥氮平、喹硫平对阿尔茨海默病患者睡眠呼吸的影响[J].医学研究与战创伤救治(原医学研究生学报),2015,17(01):8.[doi:10.3969/j.issn.1672-271X.2015.01.003]
　LIN Xiao-yan,QIU Jing,WANG Rui,et al.Effects of olanzapine and quetiapine on sleep-breathing in patients with Alzheimer disease[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2015,17(6):8.[doi:10.3969/j.issn.1672-271X.2015.01.003]
[3]汪勇,赵武伟,汪朝晖,等.小剂量奥氮平与奋乃静治疗肝移植术后精神障碍的对照研究[J].医学研究与战创伤救治(原医学研究生学报),2016,18(06):572.[doi:10.3969/j.issn.1672-271X.2016.06.004]
　WANG Yong,ZHAO Wu-wei,WANG Zhao-hui,et al.Treatment of patients with mental disorders after liver transplantation by using olanzapine or perphenazine: a control study[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2016,18(6):572.[doi:10.3969/j.issn.1672-271X.2016.06.004]
[4]李晞,时丽,姚尚武,等.帕利哌酮缓释片联合奥氮平对精神分裂症患者血清脑源性神经营养因子和神经生长因子水平及对代谢综合征影响[J].医学研究与战创伤救治(原医学研究生学报),2021,23(04):368.[doi:10.3969/j.issn.1672-271X.2021.04.007]
　LI Xi,SHI Li,YAO Shang-wu,et al.Analysis of the effect of pallidone sustained release tablets combined with olanzapine on serum BDNF, NGF levels and metabolic syndrome in schizophrenics[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2021,23(6):368.[doi:10.3969/j.issn.1672-271X.2021.04.007]

备注/Memo

备注/Memo:
-
更新日期/Last Update: 2020-12-01